Skystar Bio-Pharmaceutical (OTC BB: SKBI), a leading Chinese-based developer and producer of veterinary pharmaceutical products, announced today that it expects to complete it’s new, state of the art manufacturing facility by the end of September. Skystar also expects to have the new facility in full compliance with the Chinese government’s new Good Manufacturing Practice (GMP) Certification Standard by this summer. GMP Certification is a new pharmaceutical manufacturing standard in which all pharmaceutical companies must be incompliance with to sell its products in China and stay in business. Those companies that are not able to adhere to these high standards will be forced to close their doors.
